PharmAbcine Inc. is a bio venture specialized in R&D of antibody treatment in the clinical stage and currently possesses core technologiessuch as potent antibody development technology using potent non-immune scFv phage display library, new-generation double target antibodyproduction technology, and antibody production technology using cancer stem cell library. Since we were established in 2008 we have been devoted to developing new cancer antibody drugs and laying a foundation for TTAC-0001 and PMC-001. We will constantly develop pipelines for sustainable growth with a vision to release a new global blockbuster bio drug by 2020 and become a global bioengineering company.